Docket No.: 03754/000K213-US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Marie Dutreix et al.

Application No.: 10/053,526

0/053,526 Confirmation No.: 1617

Filed: January 18, 2002 Art Unit: 1634

For: METHODS AND COMPOSITIONS FOR

EFFECTING HOMOLOGOUS

RECOMBINATION

Examiner: J. N. Fredman

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

No item of information contained in this Information Disclosure Statement was known to an individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement (37 CFR 1.97(e)(2)).

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 23, 2004

Respectfully submitted,

Kristin E. Behrendt

Registration No.: 45,599

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 Sheet

Complete if Known				
Application Number	10/053,526			
Filing Date	January 18, 2002			
First Named Inventor	Marie Dutreix			
Art Unit	1634			
Examiner Name	J. N. Fredman			
Attorney Docket Number	03754/000K213-US0			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	THIBAUT MICHEL, et al., "Cationic phosphoramidate α-oligonucleotides efficiently target single-stranded DNA and RNA and inhibit hepatitis C virus IRES-mediated translation", Nucleic Acids Research, Vol. 3, No. 18, July 2003, ppp. 5282-5290.	
	СВ	VASQUEZ, KAREN M., et al., "Specific Mutations Induced by Triplex-Forming Oligonucleotides in Mice", Science, Vol. 290, October 2000, pp. 530-533.	
	CC	VASQUEZ, KAREN M., et al., "Chromosome Targeting at Short Polypurine Sites by Cationic Triplex-forming Oligonucleotides," The Journal of Biological Chemistry, Vol. 276, No. 42, October 2001, pp. 38536-38541.	
	CD	BAILEY, CHERYL P., et al., "Cationic oligonucleotides can mediate specific inhibition of gene expression in Xenopus oocytes," Nucleic Acids Research, Vol. 26, No. 21, 1998, pp. 4860-4867.	
	CE	DAGLE, JOHN M., "Positively charged oligonucleotides overcome potassium-medited inhibition of triplex DNA formation," Nucleic Acids Research, Vo. 24, No. 11, 1996, pp. 2143-2149.	
	CF	HILLBRAND, STEFAN, et al, "5-Substituted 2-Aminopyridine C-Nucleosides as Protonated Cytidine Equivalents: Increasing Efficiency and Selectivity in DNA Triple-Helix Formation," J. Am. Chem. Soc., 119, 1997, pp.5499-5511.	
	CG	CASSIDY, SARAH A., et al., "Recognition of GC base pairs by triplex forming oligonucleotides containing nucleosides derived from 2-aminopyridine," Nucleic Acids Research, Vol. 25, No. 24, 1997, pp. 4891-4898.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.